The United States Patent and Trademark Office (USPTO) has issued a patent grant, US12584120B2, to AstraZeneca AB for a novel pharmacophore of PCSK9 inhibitors and related heteroaryl compounds. This patent, effective March 24, 2026, covers specific chemical compounds designed to bind the PCSK9 protein, which is a key target in managing cholesterol levels and cardiovascular disease.

This grant signifies a new intellectual property right for AstraZeneca in the area of cardiovascular drug development. While this is a patent grant and not a regulatory rule imposing obligations on other entities, it is crucial for pharmaceutical companies and drug manufacturers operating in the PCSK9 inhibitor space to be aware of this granted patent. Companies should ensure their research, development, and commercialization activities do not infringe upon the claims of this patent to avoid potential legal disputes and intellectual property challenges.